Armistice Capital Reports 9.46% Stake in MacroGenics, Inc. (MGNX)

On May 15, 2026, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G/A reporting a significant position in MacroGenics, Inc. (MGNX). The filing indicates that the reporting persons beneficially own 6,012,000 shares of common stock, representing a 9.46% ownership stake in the company. This holding is managed through the Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. The reported shares represent an increase from a previous reported position of zero, suggesting a new or rebuilt significant stake as of the event date on March 31, 2026. The filing specifies that the securities were acquired in the ordinary course of business and are not held for the purpose of influencing or changing the control of the issuer. Armistice Capital and Steven Boyd share voting and dispositive power over the reported shares. The filing marks the seventh amendment to their Schedule 13G for this issuer.